DOCSLIB.ORG

Supp. Fig 1 BA Selection of Common Differentially Expressed

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supp. Fig 1 BA Selection of Common Differentially Expressed Supp. Fig 1 Overlap 2 A Overlap 1 Overlap 2 Overlap 3 Overlap 1 Overlap 3 HLH_up COVID-19_PBL_up COVID-19_PBMCs_up COVID-19_swab_up COVID-19_swab2_NIRD/OIRD_up COVID-19_scRNA cohort1_up COVID-19_scRNA cohort2_up B No overlap HLH_down COVID-19_PBL_down COVID-19_PBMCs_down COVID-19_swab_down COVID-19_swab2_NIRD/OIRD_down COVID-19_scRNA cohort1_down COVID-19_scRNA cohort2_down Selection of common differentially expressed genes (DEGs) across different COVID-19 datasets and the HLH dataset. (A and B) Venn diagrams displaying the number of up-regulated (A) and down-regulated (B) DEGs present in each dataset grouped by sample type (Overlap1; blood samples, Overlap2; swab samples) and sequencing platform (Overlap3; single cell RNA sequencing (scRNAseq) samples) and their intersections showing number of overlapping genes (bold) between COVID-19 datasets and the HLH dataset. Datasets are differentiated by colors according to legend. Supp. Fig 2 A B DotPlot by GO secretory vesicle exocytic vesicle multivesicular body membrane Adjusted.P.value primary lysosome 0.04 lysosome 0.03 melanosome DotPlot by GO 0.02 pigment granule 0.01 secretory vesicle multivesicular body exocytic vesicle azurophil granule specific granule Adjusted.P.value multivesicular body membraneGO cathegory Combined.Score primary lysosome late endosome membrane 0.04 2000 lysosome lytic vacuole 0.03 4000 specific granule lumen melanosome 0.02 6000 secretory granule lumen pigment granule 0.01 multivesicular body azurophil granule lumen azurophil granule 0 2000 4000 6000 specific granule Combined.Score GO cathegory Combined.Score C 13 D 12 14 late endosome membrane 2000 12 15 lytic vacuole 4000 13 14 11 13 16 specific granule lumen 6000 secretory granule lumen 1415 11 17 azurophil granule lumen 12 0 102000 4000 6000 Combined.Score 1615 18 10 11 RAB27A RAB27A AP3B1AP3B1 UNC13D PRF1UNC13D STXBP2STX11 PRF1 AP3B1 STXBP2STX11STXBP2 LYST −Log10 p.adj LYST PRF1PRF1 LYSTLYST −Log10 p.adj STX11 LYST −Log10 p.adj STXBP2STX11 AP3B1 UNC13D STXBP2 9 PRF1UNC13D STX11 RAB27A UNC13DRAB27A 44 AP3B1RAB27A 4 3 3 9 3 22 10 2 1 8 1 1 1 1 00 0 8 9 2 2 7 2 8 7 3 3 3 6 7 4 6 4 4 5 5 6 5 Molecular relationships between COVID-19 and fHLH. (A and B) Dot plots of most significant (A) cellular components (CCs) and (B) biological processes (BPs) enriched by the 7 genes causing fHLH due to inborn errors of immunity. Enriched signaling pathways were analyzed by Gene Ontology CC and BP 2021 databases using the Enrichr online tool. (C and D) Circular heatmap showing the 7 fHLH genes and their association with the (C) CCs and (D) BPs. CCs (1-15) and BPs (1-18) are numbered as shown in A and B, respectively. -Log10 of adjusted p value shows the enrichment of each term. Supp. Fig 3 A Gene Expression 40 20 0 −20 Gene ANXA3Expression SLC2A3 ARG1 FCAR CD55 IL1R1 CEACAM1 IL1RN MGAM IL1RAP TNFAIP6 SOD2 IL1B ABCA1 MMP8 20 TCN1 CEACAM6 CRISP3 MMP9 10 ADGRG3 LRG1 CEACAM8 0 OLFM4 ABCA13 DEFA4 −10 CTSG LTF CAMP MMP8 PGLYRP1 SLPI S100P CXCL16 CXCL16 FURIN FURIN MPP1 GPR84 CYSTM1 IL1R1 CD177 MCEMP1 C3AR1 IL1RAP IL10 CLEC5A CD44 CEACAM1 OLR1 PTX3 IL1RN EREG SERPINB10 SLC7A5 CEACAM6 ZC3H12A TNFAIP3 NFKB1 CEACAM8 NLRP3 OSM TRIB1 expression OLR1 TREM1 SLC7A11 1 PGLYRP1 EGR1 BPI 0.5 Controls LCN2 CD177 MPO 0 INAVA AREG −0.5 MPP1 ELANE AZU1 −1 C3AR1 RNASE3 RETN CD63 IL10 RAB13 SEMA6B GYPB CLEC5A GYPA SNCA HBD CD44 SUCNR1 CDK1 EREG MMP1 THBS1 CXCL2 SLC7A5 CXCL3 PLAU PLAUR GYPB DOCK4 EDN1 PDE4B GYPA F3 FFAR2 NLRP3 CD274 ICAM1 RIPK2 MMP1 TNF CCRL2 ACOD1 SUCNR1 CCL7 IL1A THBS1 SDC2 HBEGF FOSL1 CXCL2 LGALS3 CCL20 NR4A3 INAVA IFNG EGR3 PTGS2 ELANE CXCL1 CXCL8 AZU1 CHI3L1 PPIF CCL22 SEMA6B CCL2 CD83 CCL4 RAB13 HBQ1 expression IL6 HBM CXCL3 CDKN1A IL1B SPHK1 1 0 F3 IL6 BPI LTF 20 20 40 TNF IL10 IL1B IL1A HBD SLPI PPIF HBM OSM MPO − IFNG PTX3 CD55 CD44 LCN2 AZU1 CD63 CCL7 CCL2 CD83 CCL4 PLAU TCN1 LRG1 OLR1 GYPA CDK1 EDN1 SDC2 IL1R1 ARG1 FCAR SOD2 MPP1 EGR1 RETN EGR3 HBQ1 CTSG GYPB SNCA IL1RN EREG TRIB1 AREG INAVA MMP8 MMP9 CAMP MMP1 RIPK2 S100P FURIN ICAM1 FFAR2 MGAM CD177 CD274 CCL20 CCL22 DEFA4 RAB13 FOSL1 C3AR1 NFKB1 NLRP3 THBS1 CXCL2 CXCL3 NR4A3 CXCL1 CXCL8 ANXA3 ABCA1 GPR84 ELANE PDE4B CCRL2 PTGS2 SPHK1 PLAUR OLFM4 TREM1 CHI3L1 ACOD1 ABCA1 IL1RAP DOCK4 HBEGF CRISP3 SLC2A3 SLC7A5 CXCL16 LGALS3 ABCA13 CLEC5A RNASE3 TNFAIP6 TNFAIP3 CYSTM1 CDKN1A SEMA6B SUCNR1 ADGRG3 MCEMP1 SLC7A11 ZC3H12A PGLYRP1 CEACAM1 CEACAM6 CEACAM8 0.5 NFKB1 SERPINB10 DOCK4 EDN1 0 RIPK2 Gene Expression −0.5 CD274 B ICAM1 30 20 −1 10 PDE4B 0 −10 MPP1 OSM CXCL16 FCAR SLC2A3 TRIB1 CD55 IL1R1 TREM1 MGAM TRIB1 IL1RAP SLC7A11 SOD2 SLC7A11 OSM EGR1 TREM1 ZC3H12A F3 IL10 PLAUR ICAM1 FFAR2 TNFAIP3 EREG NLRP3 PTGS2 EDN1 CD44 F3 CXCL1 TNFAIP6 IL1RN CHI3L1 CD274 C3AR1 IL1A EGR3 MMP8 ABCA13 PTX3 CXCL8 SERPINB10 TCN1 OLFM4 CCL7 CEACAM6 BPI IL1A CEACAM8 CRISP3 LTF TNF MPO DEFA4 CTSG CCRL2 OLR1 CDK1 ACOD1 INAVA GYPA HBD SDC2 GYPB RAB13 LCN2 HBEGF RNASE3 RETN ELANE expression LGALS3 AZU1 CAMP 1 NR4A3 PGLYRP1 SUCNR1 0.5 CLEC5A CCL20 GPR84 0 CEACAM1 PLAU −0.5 IFNG SLPI THBS1 −1 COVID-19 AREG CCL4 CCL20 ANXA3 CD83 CYSTM1 MCEMP1 CD177 CCL2 ARG1 FURIN ADGRG3 CCL22 LRG1 CD63 IL6 SEMA6B MMP9 S100P SPHK1 MMP1 CXCL3 SNCA SLC7A5 FOSL1 0 CHI3L1 20 20 LGALS3 IL6 BPI LTF HBQ1 − TNF IL10 IL1B HBD SLPI HBM PPIF HBM MPO IFNG PTX3 SPHK1 CD55 CD44 LCN2 CD63 AZU1 PLAU TCN1 OLR1 LRG1 EDN1 CDK1 IL1R1 FCAR ARG1 SOD2 RETN HBQ1 CTSG NFKB1 SNCA AREG INAVA MMP8 MMP9 CAMP S100P ICAM1 MGAM DOCK4 CD177 DEFA4 FOSL1 NFKB1 C3AR1 CXCL1 CXCL8 NR4A3 THBS1 ANXA3 GPR84 PDE4B PTGS2 ELANE SPHK1 PLAUR OLFM4 CHI3L1 ABCA1 ACOD1 CRISP3 RIPK2 SLC2A3 LGALS3 ABCA13 CLEC5A PDE4B RNASE3 TNFAIP6 TNFAIP3 CYSTM1 CDKN1A ADGRG3 MCEMP1 CCRL2 SLC7A11 ZC3H12A PGLYRP1 ACOD1 CEACAM6 CEACAM8 CEACAM1 CCL7 FFAR2 IL1B SERPINB10 CXCL1 CCL22 EGR1 CXCL8 EGR3 PTGS2 HBEGF NR4A3 CXCL2 PPIF CD83 CDKN1A IL6 SDC2 CCL2 CCL4 IFNG TNF 0 F3 IL6 BPI LTF 10 10 20 30 TNF IL10 IL1A IL1B HBD SLPI HBM PPIF OSM MPO − IFNG PTX3 CD55 CD44 LCN2 AZU1 CD63 CCL7 CD83 CCL2 CCL4 PLAU TCN1 OLR1 LRG1 GYPA EDN1 CDK1 SDC2 IL1R1 MPP1 FCAR SOD2 RETN ARG1 HBQ1 EGR1 EGR3 CTSG GYPB SNCA TRIB1 EREG IL1RN AREG INAVA MMP8 CAMP MMP9 MMP1 RIPK2 S100P ICAM1 FURIN FFAR2 MGAM CD274 CCL20 CD177 CCL22 DEFA4 RAB13 FOSL1 NLRP3 C3AR1 THBS1 CXCL3 NFKB1 CXCL1 CXCL8 NR4A3 CXCL2 ELANE GPR84 ANXA3 SPHK1 ABCA1 PDE4B CCRL2 PTGS2 PLAUR OLFM4 TREM1 CHI3L1 ACOD1 IL1RAP DOCK4 HBEGF CRISP3 SLC2A3 SLC7A5 CXCL16 LGALS3 ABCA13 CLEC5A RNASE3 TNFAIP3 TNFAIP6 CYSTM1 CDKN1A SEMA6B SUCNR1 ADGRG3 MCEMP1 SLC7A11 ZC3H12A PGLYRP1 CEACAM6 CEACAM8 CEACAM1 SERPINB10 Bivariate correlation of cytokine/chemotaxis and neutrophil-mediated immunity genes. (A and B) Bivariate correlation analysis and hierarchical clustering of cytokine/chemotaxis and neutrophil- mediated immunity genes in (A) controls and (B) COVID-19 patients. The color scale bar (-1 to 1) corresponds to negative and positive correlations, respectively. Bar plots at the top and side of the correlogram show the sum of data points in each column and row, respectively. Supp. Fig 4 A DotPlot by GO B positive regulation of cholesterol esterification Regulation of blood coagulation regulation of complement activation Extracellular matrix organization regulation of immune effector process DotPlot by GO Regulation of endopeptidase activity regulation of humoral immune response Neutrophil degranulation/ positive regulation of cholesterol esterification Neutrophil mediated immunity platelet degranulation regulation of complement activation Cellular protein metabolic process regulation of cholesterol esterification Combined.Score regulation of immune effector process negative regulation of peptidase activity 500 Regulation of complement activation/ 1000 negative regulationregulation of blood of humoral coagulation immune response Regulation of humoral immune response 1500 negative regulation of endopeptidase activity Platelet degranulation/ platelet degranulation Regulated exocytosis regulated exocytosis Adjusted.P.value regulation of cholesterol esterification regulation of endopeptidase activity GO cathegory negative regulation of peptidase activity 1e−04 regulation of blood coagulation Combined.Score post−translationalnegative protein regulation modification of blood coagulation 5e500−05 1000 cellular protein metabolic process negative regulation of endopeptidase activity 1500 neutrophil degranulation regulated exocytosis Adjusted.P.value neutrophil activation involved in immune response regulation of endopeptidase activity GO cathegory neutrophil mediated immunity 1e−04 receptor−mediatedregulation endocytosis of blood coagulation 5e−05 extracellular matrix organization post−translational protein modification 400 800 1200 cellular protein metabolic process Combined.Score neutrophil degranulation log2 Protein Abundance C neutrophil activation involved in immune response 20 0 neutrophil mediated immunity −20 SERPINA1receptor−mediated endocytosis PIGR QSOX1 A1BGextracellular matrix organization GSN 400 800 1200 AHSG Combined.Score CFP expression CRISP3 4 HSP90AA1 HSPA8 2 ALDOA HSPA1B 0 EEF1A1 −2 HSP90AB1 GPI −4 S100A9 −6 S100A8 SERPINB1 B4GALT1 PSMA5 FTL LTA4H 0 50 ICU1 ICU2 ICU3 ICU4 ICU5 ICU6 ICU7 ICU8 ICU9 100 − ICU10 ICU11 ICU12 ICU13 ICU14 ICU15 ICU16 ICU17 ICU18 ICU19 ICU20 ICU21 ICU22 ICU23 ICU24 ICU25 ICU26 ICU27 ICU28 ICU29 ICU30 ICU31 ICU32 ICU33 ICU34 ICU35 ICU36 ICU37 ICU38 ICU39 ICU40 ICU41 ICU42 ICU43 ICU44 ICU45 ICU46 ICU47 ICU48 ICU49 ICU50 ICU51 − nonICU1 nonICU2 nonICU3 nonICU4 nonICU5 nonICU6 nonICU7 nonICU8 nonICU9 nonICU10 nonICU11 nonICU12 nonICU13 nonICU14 nonICU15 nonICU16 nonICU17 nonICU18 nonICU19 nonICU20 nonICU21 nonICU22 nonICU23 nonICU24 nonICU25 nonICU26 nonICU27 nonICU28 nonICU29 nonICU30 nonICU31 nonICU32 nonICU33 nonICU34 nonICU35 nonICU36 nonICU37 nonICU38 nonICU39 nonICU40 nonICU41 nonICU42 nonICU43 nonICU44 nonICU45 nonICU46 nonICU47 nonICU48 nonICU49 nonICU50 nonICU51 nonICU52 Significant immune pathways and dysregulated molecules obtained from proteomics analyses of plasma from severe COVID-19 when compared to mild disease. (A) Mass spectrometry (LC-MSMS) detected a total of 503 proteins in the plasma of COVID-19 patients and 158 of them were differentially expressed between COVID-19_ICU and COVID-19_nonICU.
Load more

Recommended publications
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Original Article Whole Exome Sequencing for Mutation Screening
    Original Article Iran J Ped Hematol Oncol. 2020, Vol 10, No 1, 38-48 Whole Exome Sequencing for Mutation Screening in Hemophagocytic Lymphohistiocytosis Edris Sharif Rahmani MSc1, Majid Fathi MSc1, Mohammad Foad Abazari MSc2, Hojat Shahraki MSc3, Vahid Ziaee Fellow4,5, Hamzeh Rahimi PhD6, Arshad Hosseini PhD1,* 1. Department of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Science. Tehran- Iran. 2. Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University, Tehran- Iran. 3. Department of Laboratory Sciences, School of Allied Medical Sciences, Zahedan University of Medical Sciences, Zahedan- Iran. 4. Pediatric Rheumatology Research Group, Rheumatology Research Center, Tehran University of Medical Sciences. Tehran- Iran. 5. Department of Pediatrics, Children’s Medical Center, Pediatrics Center of Excellence, Tehran University of Medical Sciences. Tehran- Iran. 6. Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran. Tehran-Iran. *Corresponding author: Dr Arshad Hosseini, Department of Medical Biotechnology, School of Allied Medicine, Iran University of Medical Sciences, Tehran, IR Iran. E-mail: [email protected]. ORCID: 0000-0002-2077-0817. Received: 18 July 2019 Accepted: 19 November 2019 Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is an immune system disorder characterized by uncontrolled hyper-inflammation owing to hypercytokinemia from the activated but ineffective cytotoxic cells. Establishing a correct diagnosis for HLH patients due to the similarity of this disease with other conditions like malignant lymphoma and leukemia and similarity among its two forms is difficult and not always a successful procedure. Besides, the molecular characterization of HLH due to the locus and allelic heterogeneity is a challenging issue.
    [Show full text]
  • Functional Assays for the Diagnosis of Primary Defects in Lymphocyte Cytotoxicity
    From the Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden FUNCTIONAL ASSAYS FOR THE DIAGNOSIS OF PRIMARY DEFECTS IN LYMPHOCYTE CYTOTOXICITY Samuel CC Chiang Stockholm 2015 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by E-print AB © Samuel CC Chiang, 2015 ISBN 978-91-7676-123-6 Back cover: 7-year collection of patient data. Image of files #1-24 holding patient information, consent forms, shipping invoices, and assay results from patient samples processed between 2008 and 2015. The open unfilled file #25 represents our anticipation of future cases. The first person to notice this gets a free lunch from Sam. Contact me! Functional Assays for the Diagnosis of Primary Defects in Lymphocyte Cytotoxicity THESIS FOR DOCTORAL DEGREE (Ph.D.) By Samuel Cern Cher, Chiang Principal Supervisor: Opponent: Assistant Professor Yenan T Bryceson Associate Professor Mirjam van der Burg Karolinska Institutet University Medical Center Rotterdam Department of Medicine, Huddinge Department of Immunology Center for Infectious Medicine Examination Board: Co-supervisors: Professor Qiang Pan Hammarström Professor Hans-Gustaf Ljunggren Karolinska Institutet Karolinska Institutet Department of Laboratory Medicine Department of Medicine, Huddinge Division of Clinical Immunology Center for Infectious Medicine Professor Ola Winqvist Professor Jan-Inge Henter Karolinska Institutet Karolinska Institutet Department of Medicine, Solna Department of Women's and Children's Health Childhood Cancer Research Unit Dr. Med. Hans Christian Erichsen Oslo University Hospital Department of Pediatric Research For the life of the body is in its blood Leviticus 17:11 ABSTRACT Cytotoxic lymphocytes encompass natural killer (NK) cells and cytotoxic T lymphocytes (CTL).
    [Show full text]
  • Discovery and Systematic Characterization of Risk Variants and Genes For
    medRxiv preprint doi: https://doi.org/10.1101/2021.05.24.21257377; this version posted June 2, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . 1 Discovery and systematic characterization of risk variants and genes for 2 coronary artery disease in over a million participants 3 4 Krishna G Aragam1,2,3,4*, Tao Jiang5*, Anuj Goel6,7*, Stavroula Kanoni8*, Brooke N Wolford9*, 5 Elle M Weeks4, Minxian Wang3,4, George Hindy10, Wei Zhou4,11,12,9, Christopher Grace6,7, 6 Carolina Roselli3, Nicholas A Marston13, Frederick K Kamanu13, Ida Surakka14, Loreto Muñoz 7 Venegas15,16, Paul Sherliker17, Satoshi Koyama18, Kazuyoshi Ishigaki19, Bjørn O Åsvold20,21,22, 8 Michael R Brown23, Ben Brumpton20,21, Paul S de Vries23, Olga Giannakopoulou8, Panagiota 9 Giardoglou24, Daniel F Gudbjartsson25,26, Ulrich Güldener27, Syed M. Ijlal Haider15, Anna 10 Helgadottir25, Maysson Ibrahim28, Adnan Kastrati27,29, Thorsten Kessler27,29, Ling Li27, Lijiang 11 Ma30,31, Thomas Meitinger32,33,29, Sören Mucha15, Matthias Munz15, Federico Murgia28, Jonas B 12 Nielsen34,20, Markus M Nöthen35, Shichao Pang27, Tobias Reinberger15, Gudmar Thorleifsson25, 13 Moritz von Scheidt27,29, Jacob K Ulirsch4,11,36, EPIC-CVD Consortium, Biobank Japan, David O 14 Arnar25,37,38, Deepak S Atri39,3, Noël P Burtt4, Maria C Costanzo4, Jason Flannick40, Rajat M 15 Gupta39,3,4, Kaoru Ito18, Dong-Keun Jang4,
    [Show full text]
  • Diagnostic Interpretation of Genetic Studies in Patients with Primary
    AAAAI Work Group Report Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology Ivan K. Chinn, MD,a,b Alice Y. Chan, MD, PhD,c Karin Chen, MD,d Janet Chou, MD,e,f Morna J. Dorsey, MD, MMSc,c Joud Hajjar, MD, MS,a,b Artemio M. Jongco III, MPH, MD, PhD,g,h,i Michael D. Keller, MD,j Lisa J. Kobrynski, MD, MPH,k Attila Kumanovics, MD,l Monica G. Lawrence, MD,m Jennifer W. Leiding, MD,n,o,p Patricia L. Lugar, MD,q Jordan S. Orange, MD, PhD,r,s Kiran Patel, MD,k Craig D. Platt, MD, PhD,e,f Jennifer M. Puck, MD,c Nikita Raje, MD,t,u Neil Romberg, MD,v,w Maria A. Slack, MD,x,y Kathleen E. Sullivan, MD, PhD,v,w Teresa K. Tarrant, MD,z Troy R. Torgerson, MD, PhD,aa,bb and Jolan E. Walter, MD, PhDn,o,cc Houston, Tex; San Francisco, Calif; Salt Lake City, Utah; Boston, Mass; Great Neck and Rochester, NY; Washington, DC; Atlanta, Ga; Rochester, Minn; Charlottesville, Va; St Petersburg, Fla; Durham, NC; Kansas City, Mo; Philadelphia, Pa; and Seattle, Wash AAAAI Position Statements,Work Group Reports, and Systematic Reviews are not to be considered to reflect current AAAAI standards or policy after five years from the date of publication. The statement below is not to be construed as dictating an exclusive course of action nor is it intended to replace the medical judgment of healthcare professionals.
    [Show full text]
  • UNIVERSITY of CALIFORNIA, SAN DIEGO Measuring
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Measuring and Correlating Blood and Brain Gene Expression Levels: Assays, Inbred Mouse Strain Comparisons, and Applications to Human Disease Assessment A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Biomedical Sciences by Mary Elizabeth Winn Committee in charge: Professor Nicholas J Schork, Chair Professor Gene Yeo, Co-Chair Professor Eric Courchesne Professor Ron Kuczenski Professor Sanford Shattil 2011 Copyright Mary Elizabeth Winn, 2011 All rights reserved. 2 The dissertation of Mary Elizabeth Winn is approved, and it is acceptable in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California, San Diego 2011 iii DEDICATION To my parents, Dennis E. Winn II and Ann M. Winn, to my siblings, Jessica A. Winn and Stephen J. Winn, and to all who have supported me throughout this journey. iv TABLE OF CONTENTS Signature Page iii Dedication iv Table of Contents v List of Figures viii List of Tables x Acknowledgements xiii Vita xvi Abstract of Dissertation xix Chapter 1 Introduction and Background 1 INTRODUCTION 2 Translational Genomics, Genome-wide Expression Analysis, and Biomarker Discovery 2 Neuropsychiatric Diseases, Tissue Accessibility and Blood-based Gene Expression 4 Mouse Models of Human Disease 5 Microarray Gene Expression Profiling and Globin Reduction 7 Finding and Accessible Surrogate Tissue for Neural Tissue 9 Genetic Background Effect Analysis 11 SPECIFIC AIMS 12 ENUMERATION OF CHAPTERS
    [Show full text]
  • Gnomad Lof Supplement
    1 gnomAD supplement gnomAD supplement 1 Data processing 4 Alignment and read processing 4 Variant Calling 4 Coverage information 5 Data processing 5 Sample QC 7 Hard filters 7 Supplementary Table 1 | Sample counts before and after hard and release filters 8 Supplementary Table 2 | Counts by data type and hard filter 9 Platform imputation for exomes 9 Supplementary Table 3 | Exome platform assignments 10 Supplementary Table 4 | Confusion matrix for exome samples with Known platform labels 11 Relatedness filters 11 Supplementary Table 5 | Pair counts by degree of relatedness 12 Supplementary Table 6 | Sample counts by relatedness status 13 Population and subpopulation inference 13 Supplementary Figure 1 | Continental ancestry principal components. 14 Supplementary Table 7 | Population and subpopulation counts 16 Population- and platform-specific filters 16 Supplementary Table 8 | Summary of outliers per population and platform grouping 17 Finalizing samples in the gnomAD v2.1 release 18 Supplementary Table 9 | Sample counts by filtering stage 18 Supplementary Table 10 | Sample counts for genomes and exomes in gnomAD subsets 19 Variant QC 20 Hard filters 20 Random Forest model 20 Features 21 Supplementary Table 11 | Features used in final random forest model 21 Training 22 Supplementary Table 12 | Random forest training examples 22 Evaluation and threshold selection 22 Final variant counts 24 Supplementary Table 13 | Variant counts by filtering status 25 Comparison of whole-exome and whole-genome coverage in coding regions 25 Variant annotation 30 Frequency and context annotation 30 2 Functional annotation 31 Supplementary Table 14 | Variants observed by category in 125,748 exomes 32 Supplementary Figure 5 | Percent observed by methylation.
    [Show full text]
  • 82599254.Pdf
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of Immunological Methods 365 (2011) 58–66 Contents lists available at ScienceDirect Journal of Immunological Methods journal homepage: www.elsevier.com/locate/jim Research paper A platform for complementation and characterization of familial haemophagocytic lymphohistiocytosis 3 mutations Edo Elstak, Arjan de Jong, Peter van der Sluijs ⁎ Department of Cell Biology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands article info abstract Article history: Mutations in UNC13D cause the severe immune disorder familial haemophagocytic Received 14 September 2010 lymphohistiocytosis type 3 (FHL3). The gene product munc13-4 is expressed in hematopoietic Received in revised form 3 December 2010 – Accepted 13 December 2010 cells and is essential for degranulation. Little information is available on genotype phenotype Available online 21 December 2010 relationships of UNC13D mutations. Some mutants may have residual functionality which qualifies them as promising targets for attempts to enhance function pharmacologically. A Keywords: problem for such analysis is the scarcity of patient material. We established assays in the RBL-2H3 Haemophagocytic lymphohistiocytosis cell line to assess functionality of lentivirally transduced munc13-4 mutants. The basic principle of Munc13-4 which is to silence endogenous rat munc13-4 and replace it with siRNA resistant YFP-tagged Degranulation human variants. Localization, degranulation, and membrane binding kinetics can now easily be RBL-2H3 analyzed quantitatively. Such a system might also be useful to screen small molecular weight compounds for their ability to rescue degranulation in cells with reduced functional munc13-4.
    [Show full text]
  • Genotype-Phenotype Study of Familial Hemophagocytic
    GENOTYPE-PHENOTYPE STUDY OF FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 3 Elena Sieni, Valentina Cetica, Alessandra Santoro, Karin Beutel, Elena Mastrodicasa, Marie Meeths, Benedetta Ciambotti, Francesca Brugnolo, Udo Zur Stadt, Daniela Pende, et al. To cite this version: Elena Sieni, Valentina Cetica, Alessandra Santoro, Karin Beutel, Elena Mastrodicasa, et al.. GENOTYPE-PHENOTYPE STUDY OF FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCY- TOSIS TYPE 3. Journal of Medical Genetics, BMJ Publishing Group, 2011, 48 (5), pp.343. 10.1136/jmg.2010.085456. hal-00601562 HAL Id: hal-00601562 https://hal.archives-ouvertes.fr/hal-00601562 Submitted on 19 Jun 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. GENOTYPE-PHENOTYPE STUDY OF FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TYPE 3 Elena Sieni1, Valentina Cetica1, Alessandra Santoro2, Karin Beutel1,8, Elena Mastrodicasa3, Marie Meeths4,5, Benedetta Ciambotti1, Francesca Brugnolo1, Udo zur Stadt6, Daniela Pende7, Lorenzo Moretta8, Gillian M. Griffiths9, Jan-Inge Henter4, Gritta Janka10, Maurizio Aricò1 1. Department Pediatric Hematology Oncology, Azienda Ospedaliero-Universitaria Meyer, Florence, Italy 2. U.O. Ematologia I, A.O. Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy 3. S.C. di Oncoematologia Pediatrica con Trapianto di CSE, Ospedale “S.M. della Misericordia” A.O.
    [Show full text]
  • Identification of Novel Genetic Mutations Leading to Rare Monogenic Inflammatory Diseases
    University College London Identification of novel genetic mutations leading to rare monogenic inflammatory diseases Ciara Maria Mulhern Thesis submitted for PhD Infection, Immunity and Inflammation Research and Teaching Department 1 UCL, Great Ormond Street, Institute of Child Health I, Ciara Maria Mulhern, state that all experimental and analytical work presented in this thesis has been carried out by myself. Where others have contributed to this work, this has been indicated in the thesis. 2 Acknowledgements Firstly, I would like to say a huge thank you to my supervisors; Dr Despina Eleftheriou, Dr Ying Hong and Professor Paul Brogan. I cannot say enough words of thanks to Despina and Ying, two incredible women. Despina has always been so supportive and encouraging. Thank you for always being consistently present throughout my PhD, even when you were on holidays, you still answered my emails. No problem is ever too small for you. Ying, Thank you for always advising me, pushing me and giving me confidence in my work. Thank you for showing me how to work as a proper scientist, how to carry out assays, plan experiments and most importantly, how to get assays to work. You have been a constant support throughout my time at ICH, not just to me but to everyone around you. Thank you as well to Paul; your constant optimism and positivity was always appreciated. Thank you for your enthusiasm and words of encouragement. I would also like to thank Ebun and Dara two mighty postdocs. Ebun, you are a constant delight, always smiling and happy. Thank you for your expertise while gene hunting; you are an absolute pleasure to work with.
    [Show full text]
  • Two Brothers with Atypical UNC13D-Related Hemophagocytic Lymphohistiocytosis Characterized by Massive Lung and Brain Involvement
    CASE REPORT published: 21 December 2017 doi: 10.3389/fimmu.2017.01892 Two Brothers with Atypical UNC13D-Related Hemophagocytic Lymphohistiocytosis Characterized by Massive Lung and Brain Involvement Giuliana Giardino1, Maia De Luca2, Emilia Cirillo1, Paolo Palma3, Roberta Romano1, Massimiliano Valeriani4, Laura Papetti4, Carol Saunders5,6,7, Caterina Cancrini2,8† and Claudio Pignata1*† 1 Department of Translational Medical Sciences, Federico II University of Naples, Naples, Italy, 2 Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Bambino Gesù Children’s Hospital, Rome, Italy, 3 Research Unit in Congenital and Perinatal Infection, Unit of Immune and Infectious Diseases, University Department of Pediatrics (DPUO), Bambino Gesù Children’s Hospital, Rome, Italy, 4 Neurology Unit, Bambino Gesù Children’s Hospital, Rome, Italy, 5 Center for Pediatric Genomic Medicine, Children’s Mercy-Kansas City, Kansas City, MO, United States, 6 School of Medicine, University of Missouri-Kansas City, Kansas City, MO, United States, 7 Department of Pathology, Children’s Mercy-Kansas City, Kansas City, MO, United States, 8 Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy Edited by: Waleed Al-Herz, Kuwait University, Kuwait Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal hyperinflammatory Reviewed by: condition. Variants in different genes have been associated with the familial forms of Takahiro Yasumi, Kyoto University, Japan the syndrome (FHL), usually presenting within the first 2 years of life. Due to increasing Anete S. Grumach, awareness of the signs and symptoms of HLH and a better understanding of the genetic Faculty of Medicine ABC, Brazil basis of the disease, FHL has been increasingly diagnosed in patients presenting beyond *Correspondence: infancy.
    [Show full text]
  • Unraveling the Cellular Origin and Clinical Prognostic Markers of Infant B-Cell Acute Lymphoblastic Leukemia Using Genome-Wide Analysis
    Acute Lymphoblastic Leukemia SUPPLEMENTARY APPENDIX Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis Antonio Agraz-Doblas, 1,2 Clara Bueno, 2# Rachael Bashford-Rogers, 3# Anindita Roy, 4,# Pauline Schneider, 5 Michela Bar - dini, 6 Paola Ballerini, 7 Gianni Cazzaniga, 6 Thaidy Moreno, 1 Carlos Revilla, 1 Marta Gut, 8,9 Maria G. Valsecchi, 10 Irene Roberts, 4,11 Rob Pieters, 5 Paola De Lorenzo, 10 Ignacio Varela, 1,$,* Pablo Menendez 2,12,13,$,* and Ronald W. Stam 5 1Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), Universidad de Cantabria-CSIC, Santander, Spain; 2Josep Carreras Leukemia Research Institute-Campus Clinic, Department of Biomedicine, School of Medicine, University of Barcelona, Spain; 3Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, UK; 4Department of Paediatrics, University of Oxford, UK; 5Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; 6Centro Ricerca Tettamanti, Department of Pediatrics, University of Milano Bicocca, Fondazione MBBM, Monza, Italy; 7Pediatric Hematology, A. Trousseau Hospital, Paris, France; 8CNAG-CRG, Center for Genomic Regulation, Barcelona, Spain; 9Universitat Pompeu Fabra, Barcelona, Spain; 10 Interfant Trial Data Center, University of Milano-Bicocca, Monza, Italy; 11 MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, UK; 12 Instituciò Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain and 13 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), ISCIII, Barcelona, Spain #These authors contributed equally to this work. $These senior authors contributed equally to this work. ©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.
    [Show full text]